TDMS Study 96022-02 Pathology Tables
NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 04/27/04 Route: GAVAGE TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Time: 13:23:35 31 WEEK SSAC/FINAL#1 Facility: Battelle Columbus Laboratory Chemical CAS #: TEFPCBMIX Lock Date: 11/04/02 Cage Range: All Reasons For Removal: 25017 Scheduled Sacrifice Removal Date Range: 05/16/00 - 05/17/00 Treatment Groups: Include 001 0 NG / 0 UG Include 002 80 NG /10 UG Include 003 240 NG /30 UG Include 004 800 NG /100 UG Include 005 2400 NG/300 UG Include 006 4000 NG/500 UG a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 1 NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 04/27/04 Route: GAVAGE TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Time: 13:23:35 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially In Study 98 86 98 86 98 86 Scheduled Sacrifice 16 10 16 10 16 10 Early Deaths Survivors Animals Examined Microscopically 10 10 10 10 10 10 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Liver (10) (10) (10) (10) (10) (10) Basophilic Focus 1 Cholangiofibrosis 1 [1.0] 2 [1.5] 2 [1.5] 1 [1.0] Eosinophilic Focus 3 2 Eosinophilic Focus, Multiple 4 3 Fatty Change, Diffuse 3 [1.7] 8 [1.4] 9 [1.4] Hepatodiaphragmatic Nodule 1 1 Hyperplasia, Nodular 1 4 Infarct 1 [3.0] Inflammation 10 [1.2] 10 [1.1] 10 [1.2] 10 [1.8] 10 [1.6] 10 [1.4] Mixed Cell Focus 3 5 1 Mixed Cell Focus, Multiple 2 3 1 6 Necrosis 1 [1.0] 1 [1.0] 1 [2.0] 2 [1.0] Pigmentation 2 [1.0] 4 [1.0] 9 [1.1] 10 [1.2] 10 [2.1] 10 [2.6] Toxic Hepatopathy 3 [1.0] 10 [2.1] 10 [2.8] Bile Duct, Fibrosis 1 [1.0] 1 [1.0] Bile Duct, Hyperplasia 1 [1.0] 10 [1.5] 10 [1.2] Centrilobular, Fibrosis 3 [1.0] 10 [1.8] 10 [2.3] Hepatocyte, Hypertrophy 2 [1.0] 4 [1.0] 8 [1.1] 10 [2.8] 10 [3.4] Hepatocyte, Multinucleated 3 [1.0] 10 [2.2] 10 [2.6] Oval Cell, Hyperplasia 8 [1.3] 10 [1.3] Portal, Fibrosis 1 [2.0] 4 [2.3] Pancreas (10) (10) (10) (10) (10) (10) Inflammation, Chronic Active 2 [1.0] Acinus, Atrophy 1 [1.0] 2 [1.0] Acinus, Vacuolization Cytoplasmic 1 [1.0] 10 [1.1] 10 [1.1] Stomach, Forestomach (10) (1) (10) Serosa, Inflammation, Chronic Active 1 [3.0] ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 2 NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 04/27/04 Route: GAVAGE TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Time: 13:23:35 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG ____________________________________________________________________________________________________________________________________ None ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (10) (10) (10) (10) (10) (10) Angiectasis 6 [1.0] 2 [1.0] 1 [1.0] 1 [1.0] Atrophy 2 [1.0] 8 [1.8] Degeneration, Cystic 1 [2.0] Hypertrophy 5 [1.2] 4 [1.8] 3 [1.0] 3 [1.7] 3 [1.0] 1 [2.0] Pituitary Gland (10) (1) (10) Angiectasis 1 [2.0] Cyst 1 [1.0] 1 [2.0] Cytoplasmic Alteration 1 [2.0] Thyroid Gland (10) (10) (10) (10) (10) (10) Inflammation, Chronic Active 1 [3.0] Follicular Cell, Hypertrophy 3 [1.3] 3 [1.0] 7 [1.3] 7 [1.4] 9 [1.8] 7 [1.7] ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (10) (10) (10) (10) (10) (10) Atrophy 6 [3.0] 7 [3.0] 7 [2.9] 4 [3.0] 1 [3.0] Uterus (10) (10) (10) (10) (10) (10) Decidual Reaction 1 Inflammation, Suppurative 1 [3.0] Metaplasia, Squamous 5 [1.6] 6 [1.7] 6 [1.7] 4 [1.8] 1 [2.0] Endometrium, Hyperplasia, Cystic 5 [1.6] 5 [2.2] 6 [1.7] 3 [1.3] 1 [2.0] 1 [2.0] ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Spleen (10) (10) Pigmentation 10 [1.2] 10 [1.3] Thymus (10) (10) (10) (9) (10) (6) Atrophy 3 [1.3] 2 [1.5] 5 [1.6] 9 [2.3] 9 [3.4] 6 [3.7] Cyst 1 [3.0] ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 3 NTP Experiment-Test: 96022-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18 Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 04/27/04 Route: GAVAGE TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) Time: 13:23:35 ____________________________________________________________________________________________________________________________________ SPRAGUE-DAWLEY RATS FEMALE 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (10) (10) Hyperplasia 2 [1.0] ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM None ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (10) (10) (10) (10) (10) (10) Hemorrhage 2 [2.0] 1 [2.0] 1 [1.0] Infiltration Cellular, Histiocyte 3 [1.0] 2 [1.0] 4 [1.0] 2 [1.0] 5 [1.0] 2 [1.0] Inflammation 1 [1.0] Inflammation, Granulomatous 1 [2.0] 2 [1.0] 2 [1.5] Metaplasia, Squamous 1 [1.0] Alveolar Epithelium, Hyperplasia 1 [1.0] Alveolar Epithelium, Metaplasia, Bronchiolar 3 [1.3] 3 [1.3] Interstitium, Fibrosis, Focal 1 [1.0] ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM None ____________________________________________________________________________________________________________________________________ URINARY SYSTEM None a Number of animals examined microscopically at site and number of animals with lesion b Average severity grade (1-minimal;2-mild;3-moderate;4-marked) Page 4 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------